Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Fiche

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Bulletin Du Cancer|March 8, 2000
[Standards, Options and Recommendations (SOR) for drafting of anatomic and surgical pathology reports or cytopathology reports in oncology]L Arnould, M Fiche, M P Blanc-Vincent, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2006
Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)L Perey, R Paridaens, H Hawle, et al.
Annales De Pathologie|May 14, 2003
[Standards, options and recommendations for the composition of anatomic and surgical pathology reports or cytopathology reports in oncology]L Arnould, M Fiche, M P Blanc-Vincent, et al.
British Journal of Cancer|May 29, 2003
Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancerL Arnould, Y Denoux, G MacGrogan, et al.
American Journal of Clinical Pathology|September 1, 1992
Primary Epstein-Barr virus infection with clonal T-cell lymphoproliferationF Gaillard, F Mechinaud-Lacroix, S Papin, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 6, 1999
Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograftF Kraeber-Bodéré, A Faibre-Chauvet, C Saï-Maurel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 1999
Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: comparison of iodine 131-labeled F(ab')2 and pretargeted bivalent hapten and evaluation of repeated injectionsF Kraeber-Bodéré, A Faivre-Chauvet, C Saï-Maurel, et al.
International Journal of Cancer|September 29, 2000
Gene amplifications detected by fluorescence in situ hybridization in pure intraductal breast carcinomas: relation to morphology, cell proliferation and expression of breast cancer-related genesM Fiche, H Avet-Loiseau, C M Maugard, et al.
International Journal of Cancer|September 30, 1999
Genetic alterations in early-onset invasive breast carcinomas: correlation of c-erbB-2 amplification detected by fluorescence in situ hybridization with p53 accumulation and tumor phenotypeM Fiche, H Avet-Loiseau, M F Heymann, et al.
European Journal of Cancer (Oxford, England : 1990)|September 25, 2012
An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancerH Bonnefoi, K Zaman, M Debled, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Bulletin Du Cancer|March 8, 2000
[Standards, Options and Recommendations (SOR) for drafting of anatomic and surgical pathology reports or cytopathology reports in oncology]L Arnould, M Fiche, M P Blanc-Vincent, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2006
Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)L Perey, R Paridaens, H Hawle, et al.
Annales De Pathologie|May 14, 2003
[Standards, options and recommendations for the composition of anatomic and surgical pathology reports or cytopathology reports in oncology]L Arnould, M Fiche, M P Blanc-Vincent, et al.
British Journal of Cancer|May 29, 2003
Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancerL Arnould, Y Denoux, G MacGrogan, et al.
American Journal of Clinical Pathology|September 1, 1992
Primary Epstein-Barr virus infection with clonal T-cell lymphoproliferationF Gaillard, F Mechinaud-Lacroix, S Papin, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 6, 1999
Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograftF Kraeber-Bodéré, A Faibre-Chauvet, C Saï-Maurel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 1999
Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: comparison of iodine 131-labeled F(ab')2 and pretargeted bivalent hapten and evaluation of repeated injectionsF Kraeber-Bodéré, A Faivre-Chauvet, C Saï-Maurel, et al.
International Journal of Cancer|September 29, 2000
Gene amplifications detected by fluorescence in situ hybridization in pure intraductal breast carcinomas: relation to morphology, cell proliferation and expression of breast cancer-related genesM Fiche, H Avet-Loiseau, C M Maugard, et al.
International Journal of Cancer|September 30, 1999
Genetic alterations in early-onset invasive breast carcinomas: correlation of c-erbB-2 amplification detected by fluorescence in situ hybridization with p53 accumulation and tumor phenotypeM Fiche, H Avet-Loiseau, M F Heymann, et al.
European Journal of Cancer (Oxford, England : 1990)|September 25, 2012
An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancerH Bonnefoi, K Zaman, M Debled, et al.
Pageof 5